LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1

洛匹那韦/利托那韦在 HIV-1 中的药代动力学

• 批准号: 7625455
• 负责人: SUSAN L KOLETAR
• 金额: $ 0.19万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-23 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625455
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Affect; Age; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Drug usage; Effectiveness; Ethnic Origin; Funding; Gender; Grant; HIV; HIV Infections; Institution; Life; Lopinavir/Ritonavir; Pharmaceutical Preparations; Race; Research; Research Personnel; Resources; Safety; Source; Thinking; United States National Institutes of Health; Weight; Woman; Women AIDS; men; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent scientific studies have suggested that more and more women are being infected with the HIV virus. It is thought that half of all the people in the world living with HIV/AIDS are women. However, most of the initial research studies on the safety and effectiveness of drugs used for treatment of HIV infection did not include a lot of women. Recent research suggests that HIV medications may affect men and women differently. ACTG 5223 will examine how different factors such as age, weight, race/ethnicity, gender, and other medications may affect these drug level results.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 最近的科学研究表明，越来越多的妇女感染了艾滋病毒。据认为，世界上感染艾滋病毒/艾滋病的人中有一半是妇女。然而，大多数关于用于治疗艾滋病毒感染的药物的安全性和有效性的初步研究并没有包括很多妇女。最近的研究表明，艾滋病毒药物可能会影响男性和女性不同。ACTG 5223将检查年龄、体重、种族/民族、性别和其他药物等不同因素如何影响这些药物水平结果。